BILLERICA, Mass.--(BUSINESS WIRE)--Bruker BioSciences Corporation (NASDAQ: BRKR) announced today that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission relating to a proposed offering of an aggregate of 10,400,000 shares of its common stock. Of these 10,400,000 shares, the Company is offering 2,200,000 shares and four of its major Laukien shareholders, specifically Isolde Laukien-Kleiner, Joerg Laukien, Dirk Laukien and Marc Laukien, are offering, in the aggregate, 8,200,000 shares. The Company and the selling shareholders have granted the underwriters a 30-day option to purchase an aggregate of up to 1,560,000 shares to cover over-allotments, if any. The Chairman, President and CEO of Bruker BioSciences, Frank H. Laukien, is not registering any of his shares of the Company in this S-3 filing.
